At 66 years old, Frances Arnold physical status not available right now. We will update Frances Arnold's height, weight, eye color, hair color, build, and measurements.
After earning her Ph.D., Arnold completed postdoctoral research in biophysical chemistry at Berkeley. In 1986, she joined the California Institute of Technology as a visiting associate. She was promoted to assistant professor in 1986, associate professor in 1992, and full professor in 1996. She was named the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry in 2000 and, her current position, the Linus Pauling Professor of Chemical Engineering, Bioengineering and Biochemistry in 2017. In 2013, she was appointed director of Caltech's Donna and Benjamin M. Rosen Bioengineering Center.
Arnold served on the Science Board for the Santa Fe Institute from 1995–2000. She was a member of the Advisory Board of the Joint BioEnergy Institute. Arnold chairs the Advisory Panel of the Packard Fellowships in Science and Engineering. She served on the President's Advisory Council of the King Abdullah University of Science and Technology (KAUST). She served as a judge for The Queen Elizabeth Prize for Engineering and worked with the National Academy of Science's Science & Entertainment Exchange to help Hollywood screenwriters accurately portray science topics.
In 2000, Arnold was elected a member of the National Academy of Engineering for integration of fundamentals in molecular biology, genetics, and bioengineering to the benefit of life science and industry.
She is co-inventor on over 40 US patents. She co-founded Gevo, Inc., a company to make fuels and chemicals from renewable resources in 2005. In 2013, she and two of her former students, Peter Meinhold and Pedro Coelho, cofounded a company called Provivi to research alternatives to pesticides for crop protection. She has been on the corporate board of the genomics company Illumina Inc. since 2016.
In 2019, she was named to the board of Alphabet Inc., making Arnold the third female director of the Google parent company.
In January 2021 she was named an external co-chair of President Joe Biden's Council of Advisors on Science and Technology (PCAST). She is working with Biden’s transition team to help identify scientists for roles in the administration. She says her main job now is to help choose PCAST’s additional members and to get to work setting a scientific agenda for the group. She has stated: “We have to reestablish the importance of science in policymaking, in decision making across the government. We need to reestablish the trust of the American people in science ... I think that PCAST can play a beneficial role in that.”
Arnold is credited with pioneering the use of directed evolution to create enzymes (biochemical molecules—often proteins—that catalyze, or speed up, chemical reactions) with improved and/or novel functions. The directed evolution strategy involves iterative rounds of mutagenesis and screening for proteins with improved functions and it has been used to create useful biological systems, including enzymes, metabolic pathways, genetic regulatory circuits, and organisms. In nature, evolution by natural selection can lead to proteins (including enzymes) well-suited to carry out biological tasks, but natural selection can only act on existing sequence variations (mutations) and typically occurs over long time periods. Arnold speeds up the process by introducing mutations in the underlying sequences of proteins; she then tests these mutations' effects. If a mutation improves the proteins' function she can keep iterating the process to optimize it further. This strategy has broad implications because it can be used to design proteins for a wide variety of applications. For example, she has used directed evolution to design enzymes that can be used to produce renewable fuels and pharmaceutical compounds with less harm to the environment.
One advantage of directed evolution is that the mutations do not have to be completely random; instead, they can be random enough to discover unexplored potential, but not so random as to be inefficient. The number of possible mutation combinations is astronomical, but instead of just randomly trying to test as many as possible, she integrates her knowledge of biochemistry to narrow down the options, focusing on introducing mutations in areas of the protein that are likely to have the most positive effect on activity and avoiding areas in which mutations would likely be, at best, neutral and at worst, detrimental (such as disrupting proper protein folding).
Arnold applied directed evolution to the optimization of enzymes (although not the first person to do so, see e.g. Barry Hall). In her seminal work, published in 1993, she used the method to engineer a version of subtilisin E that was active in the organic solvent DMF, a highly unnatural environment. She carried out the work using four sequential rounds of mutagenesis of the enzyme's gene, expressed by bacteria, through error-prone PCR. After each round she screened the enzymes for their ability to hydrolyze the milk protein casein in the presence of DMF by growing the bacteria on agar plates containing casein and DMF. The bacteria secreted the enzyme and, if it were functional, it would hydrolyze the casein and produce a visible halo. She selected the bacteria that had the biggest halos and isolated their DNA for further rounds of mutagenesis. Using this method, she designed an enzyme that had 256 times more activity in DMF than the original.
She has further developed her methods and applied them under different selection criteria in order to optimize enzymes for different functions. She showed that, whereas naturally evolved enzymes tend to function well at a narrow temperature range, enzymes could be produced using directed evolution that could function at both high and low temperatures. In addition to improving the existing functions of natural enzymes, Arnold has designed enzymes that perform functions for which no previous specific enzyme existed, such as when she evolved cytochrome P450 to carry out cyclopropanation and carbene and nitrene transfer reactions.
In addition to evolving individual molecules, she has used directed evolution to co-evolve enzymes in biosynthetic pathways, such as those involved in the production of carotenoids and L-methionine in Escherichia coli (which has the potential to be used as a whole-cell biocatalyst). She has applied these methods to biofuel production. For example, she evolved bacteria to produce the biofuel isobutanol; it can be produced in E. coli bacteria, but the production pathway requires the cofactor NADPH, whereas E. coli makes the cofactor NADH. To circumvent this problem, she evolved the enzymes in the pathway to use NADH instead of NADPH, allowing for the production of isobutanol.
Arnold has also used directed evolution to design highly specific and efficient enzymes that can be used as environmentally-friendly alternatives to some industrial chemical synthesis procedures. She, and others using her methods, have engineered enzymes that can carry out synthesis reactions more quickly, with fewer by-products, and in some cases eliminating the need for hazardous heavy metals.
She uses structure-guided protein recombination to combine parts of different proteins to form protein chimeras with unique functions. She developed computational methods, such as SCHEMA, to predict how the parts can be combined without disrupting their parental structure, so that the chimeras will fold properly, and then applies directed evolution to further mutate the chimeras to optimize their functions.
At Caltech, Arnold runs a laboratory that continues to study directed evolution and its applications in environmentally-friendly chemical synthesis and green/alternative energy, including the development of highly active enzymes (cellulolytic and biosynthetic enzymes) and microorganisms to convert renewable biomass to fuels and chemicals. A paper published in Science in 2019, with Inha Cho and Zhi-Jun Jia, has been retracted on January 2, 2020, as the results were found to be not reproducible.
As of 2021, Arnold has an h-index of 135 according to Google Scholar.